Endothelial and endothelial like cells produced from fibroblasts and uses related thereto
This disclosure relates to endothelial or endothelial like cells cultured from fibroblasts exposed to transcription factor ETV2. In certain embodiments, the disclosure relates to methods of producing endothelial or endothelial like cells comprising exposing fibroblasts with ETV2 under conditions such that the fibroblasts are modified to form a pool of cells expressing increased levels of endothelium surface markers compared to the fibroblasts. In certain embodiments, the disclosure relates to using endothelial like cells reported herein for the treatment of vascular, cardiac, and wound healing indications.
1. A method of producing cells with increased levels of endothelium surface markers comprising exposing fibroblasts with ETV2 under conditions such that the fibroblasts are modified to form a pool of cells expressing increased levels of KDR and CDH5 compared to the fibroblasts,
wherein exposing fibroblasts with ETV2 is transfecting the fibroblasts with a recombinant vector encoding ETV2 under conditions such that ETV2 is formed in the cells and
wherein the fibroblasts do not comprise a recombinant vector that encodes and expresses FOXC2.
2. The method of claim 1 , wherein the pool of cells express increased levels of the surface markers PECAM1 and TEK.
3. The method of claim 1 , further comprising the step of purifying the pool of cells by selecting cells that express KDR providing purified KDR cells.
4. The method of claim 3 , further comprising contacting the purified KDR cells with valproic acid.
5. A method of producing cells with increased levels of endothelium surface markers comprising exposing fibroblasts with ETV2 under conditions such that the fibroblasts are modified to form a pool of cells expressing increased levels of KDR and CDH5 compared to the fibroblasts,
wherein exposing fibroblasts with ETV2 is transfecting the fibroblasts with a recombinant vector encoding a single transcription factor consisting of ETV2 under conditions such that ETV2 is formed in the cells.
6. The method of claim 5 , further comprising the step of purifying the pool of cells by selecting cells that express KDR providing purified KDR cells.
7. The method of claim 6 , further comprising contacting the purified KDR cells with valproic acid.